Who Pays My Doctor?

Healthcare provider profile · identity verified

Jeffrey Jon Hansen, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · VANCOUVER, WA · NPI 1356410419

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jeffrey Jon Hansen, M.D. received $491,852.57 in general payments during 2025 across 590 reported records.

Neurocrine BioSciences, Inc. accounted for 22.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 16 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Auvelity, Ingrezza, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Auvelity by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$491,852.57

590 reported records · 13 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $112,280.6922.8%1152025
ABBVIE INC. Unresolved — no canonical attribution shown $91,131.9718.5%962025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $62,513.4712.7%562025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $52,373.2310.7%652025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $49,715.3010.1%542025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $28,902.565.9%472025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $28,764.435.8%522025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $26,653.785.4%382025
Alkermes, Inc. Unresolved — no canonical attribution shown $20,360.524.1%262025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $18,975.193.9%292025
Supernus Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $124.090.0%102025
Collegium Pharmaceutical, Inc. Unresolved — no canonical attribution shown $29.140.0%12025
Lundbeck LLC Unresolved — no canonical attribution shown $28.200.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$335,993.00110
Travel and Lodging$65,385.67180
Consulting Fee$52,868.0010
Honoraria$25,025.0010
Food and Beverage$12,569.03279
Education$11.871

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $112,204.71 113 2025
Source payment records
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $86,176.37 93 2025
Source payment records
SPRAVATO
Normalized: spravato		 Drug Janssen Pharmaceuticals, Inc $62,513.47 56 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $52,373.23 65 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $36,832.76 40 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $28,902.56 47 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $28,641.93 41 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $26,653.78 38 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $20,360.52 26 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $18,975.19 29 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $12,882.54 14 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Otsuka America Pharmaceutical, Inc. $133.58 11 2025
Source payment records
Qelbree
Normalized: qelbree		 Drug Supernus Pharmaceuticals, Inc. $124.09 10 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $118.45 7 2025
Source payment records
Jornay PM
Normalized: jornay pm		 Drug Collegium Pharmaceutical, Inc. $29.14 1 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug Otsuka America Pharmaceutical, Inc. $17.12 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
ABILIFY MAINTENA
abilify maintena		 2025 Abilify Maintena 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
Auvelity
auvelity		 2025 Auvelity 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D
INGREZZA
ingrezza		 2025 Ingrezza 2024 35
Beneficiary count suppressed		 exact normalized Medicare Part D
VRAYLAR
vraylar		 2025 Vraylar 2024 27
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 VRAYLAR
open payments reported associated product		 CMS Open Payments — General Payments
377741 supporting records · 62704 recipient NPIs · example record 1201352550 		Vraylar · 2024
Exact normalized brand match · 1 Part D row		 27 suppressed by CMS
Axsome Therapeutics, Inc.
Exact reporting entity; no affiliate inference		 2025 Auvelity
open payments reported associated product		 CMS Open Payments — General Payments
116023 supporting records · 35298 recipient NPIs · example record 1235293064 		Auvelity · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS
Lundbeck LLC
Exact reporting entity; no affiliate inference		 2025 ABILIFY MAINTENA
open payments reported associated product		 CMS Open Payments — General Payments
2902 supporting records · 986 recipient NPIs · example record 1251759994 		Abilify Maintena · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Neurocrine BioSciences, Inc.
Exact reporting entity; no affiliate inference		 2025 INGREZZA
open payments reported associated product		 CMS Open Payments — General Payments
126456 supporting records · 27390 recipient NPIs · example record 1242766729 		Ingrezza · 2024
Exact normalized brand match · 1 Part D row		 35 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 ABILIFY MAINTENA
open payments reported associated product		 CMS Open Payments — General Payments
27924 supporting records · 10497 recipient NPIs · example record 1227267721 		Abilify Maintena · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Teva Pharmaceuticals USA, Inc.
Exact reporting entity; no affiliate inference		 2025 AUSTEDO
open payments reported associated product		 CMS Open Payments — General Payments
28 supporting records · 15 recipient NPIs · example record 1247249192 		Austedo · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Escitalopram OxalateEscitalopram Oxalate12722
AripiprazoleAripiprazole9515
AlprazolamAlprazolam8811
ClonazepamClonazepam7111
LamotrigineLamotrigine56suppressed
Trazodone HclTrazodone Hcl55suppressed
ClozapineClozapine52suppressed
Buspirone HclBuspirone Hcl49suppressed
Sertraline HclSertraline Hcl46suppressed
Bupropion XlBupropion Hcl41suppressed
Duloxetine HclDuloxetine Hcl39suppressed
Quetiapine FumarateQuetiapine Fumarate39suppressed
LorazepamLorazepam37suppressed
Zolpidem TartrateZolpidem Tartrate37suppressed
IngrezzaValbenazine Tosylate35suppressed
TrintellixVortioxetine Hydrobromide31suppressed
MirtazapineMirtazapine28suppressed
VraylarCariprazine Hcl27suppressed
Divalproex Sodium ErDivalproex Sodium24suppressed
Lithium CarbonateLithium Carbonate24suppressed
Lisdexamfetamine DimesylateLisdexamfetamine Dimesylate23suppressed
OlanzapineOlanzapine23suppressed
Divalproex SodiumDivalproex Sodium22suppressed
Fluoxetine HclFluoxetine Hcl22suppressed
DiazepamDiazepam18suppressed
GabapentinGabapentin18suppressed
Haloperidol DecanoateHaloperidol Decanoate18suppressed
Methylphenidate HclMethylphenidate Hcl18suppressed
Paroxetine HclParoxetine Hcl15suppressed
RisperidoneRisperidone14suppressed
ArmodafinilArmodafinil13suppressed
Abilify MaintenaAripiprazole12suppressed
AustedoDeutetrabenazine12suppressed
Citalopram HbrCitalopram Hydrobromide12suppressed
Imipramine HclImipramine Hcl12suppressed
AuvelityDextromethorphan Hbr/Bupropion11suppressed
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $491,852.57 · 590 records Neurocrine BioSciences, Inc. ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, Jornay PM, LYBALVI, Qelbree, REXULTI, SPRAVATO, UZEDY, VRAYLAR 6 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error